[{"id":"067fae8a-0794-4faa-b039-26fcd91b764b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06842498","created_at":"2025-02-25T12:32:24.274Z","updated_at":"2025-02-25T12:32:24.274Z","phase":"Phase 2","brief_title":"A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","source_id_and_acronym":"NCT06842498","lead_sponsor":"FibroGen","biomarkers":" CD46","pipe":"","alterations":" ","tags":["CD46"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FG-3246"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-24"},{"id":"f8d3f496-5502-495c-b764-10b466a479fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT03575819","created_at":"2024-02-01T15:19:09.051Z","updated_at":"2024-07-02T16:35:21.359Z","phase":"Phase 1","brief_title":"A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","source_id_and_acronym":"NCT03575819","lead_sponsor":"Fortis Therapeutics, Inc.","biomarkers":" CD46","pipe":"","alterations":" ","tags":["CD46"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FG-3246"],"overall_status":"Completed","enrollment":" Enrollment 56","initiation":"Initiation: 02/04/2019","start_date":" 02/04/2019","primary_txt":" Primary completion: 11/16/2023","primary_completion_date":" 11/16/2023","study_txt":" Completion: 11/22/2023","study_completion_date":" 11/22/2023","last_update_posted":"2024-02-01"}]